©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Variants of Tissue-type Plasminogen Activator with Substantially Enhanced Response and Selectivity toward Fibrin Co-factors (*)

(Received for publication, June 7, 1995)

Leif Strandberg Edwin L. Madison (§)

From the Scripps Research Institute, Department of Vascular Biology, La Jolla, California 92037

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Unlike most proteases, tissue-type plasminogen activator (t-PA) is not synthesized as an inactive precursor or zymogen. Instead, the single-chain ``proenzyme'' form of t-PA possesses very significant catalytic activity. Recent investigations of the molecular basis of the unusually high enzymatic activity of single-chain t-PA have focused attention upon Asp-194, a residue that is invariant among chymotrypsin-like enzymes. The critical role of this residue in securing the active conformation of mature chymotrypsin-like enzymes has been discussed extensively. Subsequent work, however, has indicated that this conserved residue can also form interactions that dramatically influence the catalytic activity of serine protease zymogens. While Asp-194 forms interactions that suppress the activity of the zymogen chymotrypsinogen, it may, by contrast, directly promote the catalytically active conformation of single-chain t-PA. To test the hypothesis that Asp-194 promotes the activity of both single- and two-chain t-PA and therefore plays opposing roles in single-chain t-PA and chymotrypsinogen, and also to examine whether this invariant residue plays an essential role in the stimulation of t-PA by fibrin, we used site-directed mutagenesis to construct the following variants of t-PA: t-PA/D194E, t-PA/D194N, t-PA/R15E,D194E, and t-PA/R15E,D194N. In the absence of fibrin, the activity of enzymes carrying a mutation at position 194 was reduced by factors of 1000-2000 compared to wild type t-PA. Similar reductions of activity were observed for both single- and two-chain variants, suggesting an important role for Asp-194 in both forms of the enzyme. The mutated enzymes, however, displayed a dramatically enhanced response to fibrin monomers. While the activity of wild type t-PA was stimulated by fibrin monomers by a factor of 960, the corresponding stimulation factor for the mutated enzymes varied from 498,000-1,050,000.


INTRODUCTION

Many critical biological processes (1, 2, 3) depend on specific cleavage of individual target proteins by serine proteases. One important example is the dissolution of blood clots in which the initiating and rate-limiting step is the activation of the circulating zymogen plasminogen by tissue-type plasminogen activator (t-PA)(^1)(4, 5) .

Unlike typical chymotrypsin-like enzymes, the single-chain or ``proenzyme'' form of t-PA possesses high catalytic activity(6, 7, 8, 9, 10, 11, 12) . In the absence of the co-factor fibrin, single-chain t-PA is approximately 8% as active as two-chain t-PA. In the presence of fibrin, however, single- and two-chain t-PA display equivalent enzymatic activity. ``Zymogen activation'' of single-chain t-PA, therefore, can be accomplished either by activation cleavage or by binding to the co-factor fibrin.

The unusually high, intrinsic enzymatic activity of single-chain t-PA may reflect both the absence of interactions, present in typical proenzymes, that suppress activity of the zymogen and the presence of interactions, absent in typical zymogens, that stabilize an active conformation of the single-chain enzyme. Recent studies suggest that the zymogen triad (Ser-32-His-40-Asp-194), which exists in strong zymogens like chymotrypsinogen but not in t-PA, is an example of the former type of interaction, and that Asp-194, (^2)together with either Lys-143 or Lys-156, may participate in the latter interactions(12, 13, 14, 15) . Asp-194, a residue that is invariant among enzymes of the chymotrypsin family, may therefore play a very different role in single-chain t-PA from the one it plays in typical serine protease zymogens.

Asp-194 forms critical interactions that profoundly influence the catalytic activity not only of serine protease zymogens but also of the corresponding mature enzymes. Upon activation cleavage of chymotrypsinogen, for example, the interaction between the side chains of His-40 and Asp-194 described above is broken as the side chain of Asp-194 rotates approximately 170° to form a strong, buried salt bridge with the new amino terminus at Ile-16(16) . This new salt bridge, which promotes enzymatic activity by securing the active conformation of the oxyanion hole and the P1 binding pocket, is present in every mature chymotrypsin-like enzyme whose structure has been determined(16, 17, 18, 19) . It seems very likely, therefore, that this salt bridge will also be present in mature two-chain t-PA, and, consequently, that interactions involving Asp-194 will influence the activity of two-chain t-PA.

To test the hypothesis that Asp-194 participates in interactions which influence the activity of both single- and two-chain t-PA and also to examine whether this invariant residue plays an essential role in the stimulation of t-PA by fibrin, we used site-specific mutagenesis to construct the following variants of t-PA: t-PA/D194E, t-PA/D194N, t-PA/R15E,D194E, and t-PA/R15E,D194N. Unlike wild type t-PA or the two single mutants, enzymes containing the R15E mutation were resistant to activation cleavage by plasmin and therefore remained in the single-chain form during assays of plasminogen activation. In the absence of fibrin, the activity of enzymes carrying a mutation at position 194, both toward plasminogen and toward small synthetic substrates, was reduced by factors varying from 1000-2000. Similar reductions in activity were observed for both the single- and two-chain forms of t-PA/D194E and t-PA/D194N. The mutated enzymes, however, displayed a dramatically enhanced response and selectivity toward fibrin co-factors.


EXPERIMENTAL PROCEDURES

Reagents

The chromogenic substrates methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-para-nitroaniline (Spec t-PA), H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroaniline diacetate salt (Spec PL), soluble fibrin (DESAFIB), Lys-plasminogen, CNBr-digested fibrinogen, and fibrinogen were purchased from American Diagnostica (Greenwich, CT). CAPS, amiloride, and imidazole were purchased from Sigma. Active plasminogen activator inhibitor type 1 (PAI-1) was a kind gift from Drs. Joe Shore, Jan Kvassman, and co-workers. Aprotinin was purchased from Boehringer Mannheim (Mannheim, Germany) and lysine-Sepharose from Pharmacia (Uppsala, Sweden).

Recombinant DNA Techniques

Buffer and reaction conditions for restriction enzymes and T4 DNA ligase were as recommended by the commercial source, New England Biolabs or Boehringer Mannheim (Mannheim, Germany). Other standard recombinant DNA techniques were performed as described(20) .

Site-directed mutagenesis was performed as described previously (21, 22) using single-stranded M13mp18 DNA containing cDNA encoding t-PA as a template. The synthetic oligonucleotides used as mutagenic primers were as follows: t-PA(D194E), 5`-CAGGGCGAGTCGGGAGG-3`; t-PA(D194N), 5`-GCCAGGGCAATTCGGGA-3`.

Following mutagenesis, single-stranded DNA was prepared from several independent phage isolates. The 290 base tracts of t-PA cDNA in these templates were sequenced completely to verify the presence of the desired mutation and the absence of any additional mutation. Double-stranded, replicative form DNA from phage containing confirmed mutations was prepared and used to isolate the 290-base pair SacI- SmaI fragment of t-PA cDNA. The mutated 290-base pair SacI-SmaI DNA fragments were then used to replace the corresponding region of cDNA encoding wild type t-PA in the eucaryotic expression vector pSVT7/t-PA(23, 24) . Vectors that direct the expression of noncleavable, single-chain variants of t-PA containing mutations at both positions 15 and 194 were constructed from the mutated plasmids described above by replacing the internal 472-base pair EcoRI fragment of t-PA cDNA with a corresponding fragment encoding the mutation R15E. All new plasmid DNAs were isolated, rechecked for the presence of the correct mutation(s), and purified by CsCl equilibrium centrifugation.

Transient Expression and Purification of Mutant t-PA

Expression vectors encoding t-PA/D194E, t-PA/D194N, t-PA/R15E,D194E, or t-PA/R15E,D194N were introduced into COS-1 cells by electroporation using a Bio-Rad Gene Pulser. 20 µg of cDNA, 100 µg of carrier DNA, and approximately 10^7 COS cells were placed into a 0.4-cm cuvette, and electroporation was performed at 320 V, 960 microfarads, and ohms = . Following electroporation, cells were incubated overnight at 37 °C in Dulbecco's modified Eagle's medium (Life Technologies Inc.) containing 10% fetal calf serum and 5 mM sodium butyrate and then washed with serum-free medium and incubated in Ultraculture serum-free media for 48 h before harvest. The use of Ultraculture serum-free media (BioWhittaker, Walkersville, MD) made it possible to harvest conditioned media for 3 consecutive days before the protein expression declined. The conditioned media were frozen in liquid nitrogen and stored at 80 °C until purification.

Prior to purification, the conditioned media were dialyzed for 48 h at 4 °C against 20 mM sodium phosphate, pH 7.0, 150 mM NaCl, 0.05% Tween 80. t-PA was then collected by three consecutive passages over 0.5 ml of lysine-Sepharose (Pharmacia), using a separate Bio-Rad Econo-Column (0.7 times 5 cm) for each t-PA variant. The columns were washed with 18 column volumes of loading buffer and eluted with 0.2 M arginine in the buffer above. Peak fractions were collected, pooled, and concentrated further before being aliquoted, frozen in liquid nitrogen, and stored at -80 °C until use.

The single-chain form of wild type and mutated enzymes was converted into the corresponding two-chain enzyme by treatment with plasmin-Sepharose as described previously(9) , and quantitative cleavage was confirmed by SDS-polyacrylamide gel electrophoresis.

General Methods with Recombinant Proteins

Concentration of conditioned media or purified enzyme was carried out in Amicon Centriprep® 30 or Centriplus® 30 concentrators according to the manufacturer's instructions. Measurement of enzyme concentrations was accomplished by enzyme-linked immunosorbent assay as described previously(25) . SDS-PAGE was performed on 12% polyacrylamide gels using the buffer system of Laemmli(26) . Proteins were visualized either by Coomassie Blue staining or by Western blotting, using the primary antibody 374B (American Diagnostica) and the ECL Western detection system from Amersham (United Kingdom).

Indirect Chromogenic Assays of Plasminogen Activation in the Presence of Various Stimulators

Standard indirect chromogenic assays were performed as described previously(23, 24, 27) . Assays were performed either in the presence of buffer, 25 µg/ml DESAFIB, 50 µg/ml cyanogen bromide fragments of fibrinogen (American Diagnostica), or 100 µg/ml fibrinogen. Assays were performed at 37 °C in microtiter plates, and the optical density at 405 nm was read every 30 s for 2 h in a Molecular Devices Thermomax.

Kinetic Analysis of Plasminogen Activation Using Indirect Chromogenic Assays

Indirect chromogenic assays of wild type and mutated variants of t-PA utilized the substrates Lys-plasminogen and Spectrozyme PL and were performed as described previously(22, 23, 24, 27) except that 0.125 mM amiloride was included in the reaction mixture(28) . Assays were performed both in the presence and absence of the co-factor DESAFIB. The concentration of Lys-plasminogen was varied from 0.0125-0.2 µM in the presence of DESAFIB and from 0.9-15 µM in the absence of the co-factor. K(m) and k values were calculated as described previously(24, 27, 29, 30) . The K(m) (0.062 mM) and k (24 s) of plasmin for Spec PL were determined under our experimental conditions using a preparation of plasmin whose activity had been measured by active site titration.

Direct Chromogenic Assays of t-PA Activity Using Activated Substrates

Direct assays of t-PA activity utilized the substrate Spec t-PA and were performed as described previously (22) except that 0.5 mM amiloride, 0.3 µg/ml aprotinin, and 0.02% Tween 80 were included in the assay.

Measurement of Second Order Rate Constants for Inhibition by PAI-1

Second order rate constants for inhibition of t-PA by PAI-1 were measured under pseudo-first order conditions as described previously(24, 27) . Briefly, enzyme and inhibitor were preincubated at 23 °C for periods of time varying from 0 to 30 min. Following preincubation, the mixtures were diluted 4-40-fold, depending on the enzyme and PAI-1 concentrations in a particular reaction, and residual enzymatic activity was measured in the indirect chromogenic assay and compared to control reactions in which PAI-1 was added after dilution and addition of fibrin, plasminogen, and Spec PL. For each enzyme, the concentrations of enzyme and inhibitor were chosen to yield several data points for which the residual enzymatic activity varied between 20 and 80% of the initial activity, and the molar excess of PAI-1 over t-PA was always more than 20-fold. Data were analyzed by plotting ln(residual activity/initial activity) versus time of preincubation and calculating the resulting slope. Division of this slope by -[PAI-1] produced the second order rate constant (M s).


RESULTS

Design, Construction, and Production of t-PA Mutants

To investigate the functional significance of Asp-194 of t-PA, we used site-directed mutagenesis to replace this residue with either a glutamic acid or an asparagine residue. The resulting variants were denoted t-PA/D194E and t-PA/D194N, respectively. Accurate measurement of the enzymatic activity toward plasminogen of the single-chain form of these variants proved difficult, however, because plasmin produced during the assay rapidly and efficiently converted the enzymes into their mature, two-chain form by cleaving the Arg-15-Ile-16 bond of the single-chain t-PAs. Consequently, to overcome this technical difficulty, we also constructed noncleavable forms of the two mutated enzymes by introducing the additional mutation R15E into the existing variants.

Wild type t-PA, t-PA/R15E, and all four variants containing a mutation at position 194 were expressed by transient expression in COS-1 cells and purified by lysine-Sepharose affinity chromatography. Since this procedure yielded almost exclusively single-chain material, two-chain t-PAs were generated by treating the enzyme preparations with plasmin-Sepharose. Quantitative conversion of the enzymes into their two-chain forms was confirmed by SDS-PAGE. As expected, variants containing the mutation R15E were not cleaved by plasmin-Sepharose (data not shown).

Kinetic Analysis of Catalytic Activity toward a Low Molecular Weight Substrate

The enzymatic activity of the single- and two-chain form of wild type t-PA and each variant toward a small synthetic substrate is listed in Table 1. Compared to wild type, two-chain t-PA, the catalytic efficiency of two-chain t-PA/D194E and t-PA/D194N is decreased by a factor of approximately 1400. Single-chain t-PA/R15E,D194E and t-PA/R15E,D194N displayed approximately an 850-fold reduction in catalytic efficiency compared to t-PA/R15E. In all cases, the observed decrease in activity was due primarily to a large decrease in k; K(m) increased by factors of only 1-3. Mutations at position 194 of t-PA, therefore, apparently affect the catalytic machinery of the enzyme, both in the single- and two-chain form, much more dramatically than they affect binding determinants for the ground state, low molecular weight substrate. It is also interesting that the mutated enzymes were activated to the same extent as wild type t-PA by conversion into the mature, two-chain form. This activation occurs mainly by decreasing K(m), suggesting that activation cleavage of the variants does not alleviate the distortion(s) of their catalytic machinery caused by the mutations at position 194.



Kinetic Analysis of Catalytic Activity toward the Physiological Substrate Plasminogen

The enzymatic activity of wild type and mutated variants of t-PA toward the natural substrate plasminogen was measured both in the presence and the absence of the co-factor fibrin. In the absence of soluble fibrin, k/K(m) for plasminogen activation by the two mutants was approximately 2000-fold lower than that of wild type t-PA, and similar decreases in activity were observed for the noncleavable, single-chain form of the mutants compared to t-PA/R15E (Table 2).



The noncleavable, single-chain mutants retained a K(m) value similar to that of single-chain t-PA/R15E, and the decrease in activity toward plasminogen was due to a reduced k. The basis of decreased activity by the two-chain forms of the mutants was more complicated and included both a large decrease in k and at least a 10-fold increase in K(m). While the k/K(m) values reported in Table 2for these two-chain variants are very reliable, precise partitioning of the catalytic efficiency of these two variants should be interpreted with caution since the high K(m) made it impossible to carry out assays at sufficiently high plasminogen concentrations to ensure optimal accuracy of individual K(m) and k values. Comparison of k/K(m) values for the single- and two-chain form of enzymes carrying mutations at position 194 indicated that activation cleavage of these variants, as with the wild type enzyme, produced an approximately 10-fold enhancement of enzymatic activity.

The activity toward plasminogen of all six enzymes utilized in this study was substantially enhanced by soluble fibrin monomers ( Table 2Table 3, and Table 4). Fibrin increased the catalytic efficiency of two-chain t-PA by a factor of 960, and this stimulation was due primarily to a decreased K(m) for plasminogen. The response of the single-chain enzyme t-PA/R15E to fibrin was even more impressive; in this case, a 9-fold increase in k and a 1400-fold decrease in K(m) combine to yield a stimulation factor of approximately 12,000. Even when compared to these large stimulation factors, however, the response of the enzymes containing mutations at residue 194 to fibrin is dramatic. In all cases, fibrin stimulation of these mutated enzymes includes substantial contributions to both K(m) and k, and fibrin stimulation factors vary from 116,000-1,050,000. For example, with t-PA/R15E,D194N, the presence of soluble fibrin increases k by a factor of 4710 and decreases K(m) by a factor of 219, resulting in a fibrin stimulation factor of 1,050,000 which is significantly larger than that reported for any other plasminogen activator.





The Effect of Different Stimulators on the Activity of t-PA Variants toward Plasminogen

The four enzymes carrying a mutation at residue 194 are not only stimulated to a much greater extent by soluble fibrin than t-PA (Table 4), but they are also significantly more selective toward fibrin co-factors than the wild type enzyme (Fig. 1). Two-chain t-PA is strongly stimulated by soluble fibrin monomers, fibrinogen, and CNBr fragments of fibrinogen, and single-chain t-PA/R15E is stimulated strongly by soluble fibrin and fibrinogen and moderately by the CNBr fragments. By contrast, although dramatically stimulated by fibrin monomers, the variants containing an asparagine residue at position 194 are virtually nonresponsive to either fibrinogen or CNBr fragments of fibrinogen, and variants containing glutamate at position 194 are only poorly (t-PA/D194E) or moderately (t-PA/R15E,D194E) stimulated by fibrinogen and nonresponsive toward the CNBr fragments.


Figure 1: Effect of different stimulators on the activities of wild type and variants of t-PA. Standard indirect chromogenic assay of plasminogen activation in the presence of either buffer (box), 25 µg/ml DESAFIB (circle), 100 µg/ml fibrinogen (&cjs2134;), or 50 µg/ml CNBr-digested fragments of fibrinogen (up triangle).



The ratio of the specific activity of a plasminogen activator in the presence of fibrin to that in the presence of fibrinogen, or ``fibrin selectivity factor,'' may be one indication of the ``clot selectivity'' an enzyme will demonstrate in vivo. An enzyme with enhanced fibrin selectivity may be able to accomplish efficient thrombolysis while displaying decreased systemic activity. Under the conditions of the assays reported here, the fibrin selectivity factor is 1.2 for two-chain t-PA and 1.0 for single-chain t-PA/R15E. All four mutated enzymes exhibit enhanced selectivity toward fibrin, having fibrin selectivity ratios of 30 (t-PA/R15E,D194E), 50 (t-PA/R15E,D194N), 60 (t-PA/D194E), or 190 (t-PA/D194N).

Inhibition of Enzymatic Activity by PAI-1

As expected from their reduced enzymatic activity, all variants containing a mutation at position 194 were less reactive toward PAI-1, the primary endogenous inhibitor of t-PA(31, 32) , than the wild type enzyme (Table 5). By contrast to their similar activities toward the substrate plasminogen, there was a clear difference in reactivity toward PAI-1 between the two mutants. Mature t-PA/D194E was inhibited by PAI-1 approximately 30-fold more rapidly than two-chain t-PA/D194N; similarly, single-chain t-PA/R15E,D194E was inhibited by PAI-1 approximately 7 times more rapidly than single-chain t-PA/R15E,D194N. The single-chain form of both variants was less reactive toward PAI-1, by a factor of 3 (D194N) or 13 (D194E), than the corresponding two-chain enzyme.




DISCUSSION

All chymotrypsin-like serine proteases that have been crystallized to date possess a salt bridge formed by the new amino-terminal residue, created by activation cleavage, and a conserved aspartic acid residue, Asp-194, which is believed to be necessary for maintenance of the active conformation of the mature enzyme(18) . Although no crystal structure of the t-PA molecule is available, it seems likely that this important ionic interaction is also present in two-chain t-PA. In this report, we describe the construction and characterization of t-PA mutants in which Asp-194 is replaced by either a glutamic acid or an asparagine. Assuming formation of the new salt bridge in two-chain t-PA, the Asp to Glu mutation is expected to introduce steric constraints on the salt bridge, while the isosteric Asp to Asn replacement would eliminate the salt bridge. The structural effect of these mutations on single-chain t-PA, however, is less predictable because both the molecular basis of the enzyme's unusually high catalytic activity and the interactions formed by Asp-194 in single-chain t-PA remain obscure.

Our data support the hypothesis that Asp-194 forms key interactions that promote the enzymatic activity of both single- and two-chain t-PA and provide the first direct evidence that this invariant residue may play opposing roles in single-chain t-PA and chymotrypsinogen. Both single- and two-chain variants of t-PA containing a mutation at position 194 displayed similarly reduced enzymatic activity toward synthetic and natural substrates. In each case, the reduced activity of the mutated enzymes resulted primarily from a decreased k, suggesting that the mutations retard the enzyme's catalytic capacity more than it's ability to bind substrate. Because it is known that interactions involving Asp-194 can dramatically influence the position and conformation of Gly-193, one possible explanation for this observation is that our mutations have disrupted a structure known as the oxyanion hole(33) . After formation of the tetrahedral intermediate, the oxyanion hole, which is formed by the main chain amide groups of Gly-193 and Ser-195, donates two hydrogen bonds to the carbonyl group of the P1 residue of the substrate (17) . This key structure, therefore, promotes catalysis, presumably enhancing k, by stabilizing the oxyanion of the transition state formed during proteolysis.

Comparison of the structures of the mature and precursor forms of trypsin(ogen) and chymotrypsin(ogen) revealed that a surprisingly large segment of these proteins, which was designated the activation domain (17) and contained portions of the primary specificity pocket, the oxyanion hole and the autolysis loop, was reorganized upon activation cleavage(16, 34, 35, 36) . This large conformational change involved 16% of the enzyme, provided the structural basis underlying enhanced activity in the mature enzyme compared to the zymogen, and was initiated by insertion of the first two residues of the newly created amino terminus into the activation pocket, where they formed the salt bridge with Asp-194 and at least seven additional, primarily hydrophobic interactions with other residues(17, 34) . Because single-chain t-PA/D194E and t-PA/D194N display an increase in activity upon activation cleavage which is similar to that observed with wild type t-PA, it is likely that insertion of the mature amino terminus, along with at least a significant part of the subsequent structural reorganization of the activation domain, occurs in both variants as well as in wild type t-PA.

Molecular details of the stimulation of t-PA by fibrin, a complex event that almost certainly involves multiple points of contact between the two proteins, remain obscure(37, 38, 39) . For single-chain t-PA, stimulation by fibrin appears to involve at least two distinct mechanisms. First, fibrin apparently stimulates both single- and -chain t-PA through a ``templating'' mechanism, or the formation of a ternary complex which greatly augments the local concentration of the enzyme and substrate(40, 41) . Second, because single- and two-chain t-PA have equivalent catalytic activity in the presence but not the absence of fibrin, it seems likely that binding to fibrin induces a conformational change in the activation domain of single-chain t-PA(7, 8) . Induction of such a conformational change in the absence of activation cleavage and concomitant generation of the mature amino terminus is particularly intriguing but not unprecedented. Similar activation of plasminogen by binding to streptokinase(42, 43, 44, 45, 46, 47) as well as activation of prothrombin by binding to staphylocoagulase(48, 49) has been described previously. Although the mechanism of this nonclassical, nonproteolytic activation of serine protease zymogens remains completely unclear, the behavior of single-chain t-PA/R15E,D194E and t-PA/R15E,D194N suggests that Asp-194 does not play an essential role in the process.

Stimulation of mature t-PA is primarily a result of a drastically reduced K(m), an observation which is consistent with the templating mechanism described above. It is uncertain, therefore, whether binding to fibrin alters the conformation of two-chain, wild type t-PA. The two-chain variants of t-PA with mutations at residue 194, however, are stimulated by fibrin to a much greater extent than the wild type enzyme, and this stimulation includes very large improvements in both K(m) and k. Consequently, while the variants possess only 0.003-0.05% of the activity of two-chain t-PA in the absence of a co-factor, they develop 3.3-6.2% the activity of the mature wild type enzyme in the presence of fibrin. It seems likely, therefore, that fibrin does induce a conformational change in both the single- and two-chain form of the variants and that this conformational change may partially compensate for the deleterious effect of the mutations.

Data in Table 2Table 3, and Table 4establish that the variants of t-PA examined in this study are stimulated by fibrin monomers to a greater extent than any previously described plasminogen activator; moreover, data in Fig. 1indicate that these variants also exhibit substantially greater selectivity toward fibrin co-factors than wild type t-PA. The activity of wild type t-PA is stimulated nearly as well by fibrinogen or cyanogen bromide fragments of fibrinogen as by fibrin monomers. By contrast, variants containing an asparagine residue at position 194 are virtually nonresponsive to either fibrinogen or CNBr fragments of fibrinogen, and variants containing glutamate at position 194 are only poorly (t-PA/D194E) or moderately (t-PA/R15E,D194E) stimulated by fibrinogen and nonresponsive toward the CNBr fragments.

While the activity assays described above revealed only small differences in reactivity toward synthetic and natural substrates between t-PA/D194E and t-PA/D194N, two-chain t-PA/D194E was significantly more reactive than mature t-PA/D194N toward the specific inhibitor PAI-1. This observation underscores our previous assertion that the interaction of t-PA with physiological substrates and inhibitors differs in significant ways(23, 24, 27) .

This study clearly demonstrates that highly specific plasminogen activators which exhibited extraordinary co-factor dependence and selectivity could have evolved by selection of catalytically destructive point mutations whose deleterious effects were partially overcome by interaction of the enzyme with fibrin. Although evolutionary events of this kind may very well explain, at least partially, the relatively modest activity of two-chain t-PA in the absence of fibrin, it is clear that the evolution of fibrin stimulation and selectivity by t-PA has not approached the maximum extent possible. Maintenance of very high enzymatic activity and/or productive interactions with vascular or extravascular stimulators that are not currently appreciated appears, therefore, to have exerted greater evolutionary pressure on t-PA than the development of maximal stimulation and selectivity toward fibrin.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants RO1 HL52475 and P01 HL31950 (to E. L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Scripps Research Institute, Dept. of Vascular Biology, 10666 N. Torrey Pines, La Jolla, CA 92037. Fax: 619-554-6402.

(^1)
The abbreviations used are: t-PA, tissue-type plasminogen activator; CAPS, 3-(cyclohexylamino)propanesulfonic acid; DESAFIB, soluble fibrin: PAGE, polyacrylamide gel electrophoresis; PAI-1, plasminogen activator inhibitor 1; Spec t-PA, methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-para-nitroaniline; Spec PL, H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroaniline diacetate salt.

(^2)
To avoid confusion, we use the chymotrypsin numbering system to designate particular residues of the protease domain of t-PA. Positions 15, 32, 40, 143, 156, and 194 of chymotrypsin correspond to residues 275, 292, 305, 416, 429, and 477, respectively, in the t-PA numbering system.


ACKNOWLEDGEMENTS

We thank Betsy Goldsmith and Martin Schwartz for critical review of this manuscript.


REFERENCES

  1. Neurath, H. (1984) Science 224,350-357 [Medline] [Order article via Infotrieve]
  2. Neurath, H. (1989) Trends Biochem. Sci. 14,268-271 [CrossRef][Medline] [Order article via Infotrieve]
  3. Neurath, H. (1986) J. Cell. Biochem. 32,35-49 [Medline] [Order article via Infotrieve]
  4. Mann, K. G., and Lorand, L. (1993) Methods Enzymol. 223,145-288 [Medline] [Order article via Infotrieve]
  5. High, K. A., and Roberts, H. R. (1995) Molecular Basis of Thrombosis and Hemostasis , Marcel Dekker, New York
  6. Ranby, M., Bergsdorf, N., and Nilsson, T. (1982) Thromb. Res. 27,175-183 [Medline] [Order article via Infotrieve]
  7. Tate, K. M., Higgins, D. L., Holmes, W. E., Winkler, M. E., Heyneker, H. L., and Vehar, G. A. (1987) Biochemistry 26,338-343 [Medline] [Order article via Infotrieve]
  8. Petersen, L. C., Johannessen, M., Foster, D., Kumar, A., and Mulvihill, E. (1988) Biochim. Biophys. Acta 952,245-254 [Medline] [Order article via Infotrieve]
  9. Boose, J. A., Kuismanen, E., Gerard, R., Sambrook, J., and Gething, M.-J. (1989) Biochemistry 28,635-643 [Medline] [Order article via Infotrieve]
  10. Urano, T., de Serrano, V. S., Urano, S., and Castellino, F. J. (1989) Arch. Biochem. Biophys. 270,356-362 [Medline] [Order article via Infotrieve]
  11. Higgins, D. L., Lamb, M. C., Young, S. L., Powers, D. B., and Anderson, S. (1990) Thromb. Res. 57,527-539 [Medline] [Order article via Infotrieve]
  12. Madison, E. L., Kobe, A., Gething, M.-J., Sambrook, J. F., and Goldsmith, E. J. (1993) Science 262,419-421 [Medline] [Order article via Infotrieve]
  13. Petersen, L. C., Boel, E., Johannessen, M., and Foster, D. (1990) Biochemistry 29,3451-3457 [Medline] [Order article via Infotrieve]
  14. Heckel, A., and Hasselbach, K. M. (1988) J. Comput.-Aided Mol. Des. 2,7-14
  15. Nienaber, V. L., Young, S. L., Birktoft, J. J., Higgins, D. L., and Berliner, L. J. (1992) Biochemistry 31,3852-3861 [Medline] [Order article via Infotrieve]
  16. Freer, S. T., Kraut, J., Robertus, J. D., Wright, H. T., and Xuong, N. H. (1970) Biochemistry 9,1997-2009 [Medline] [Order article via Infotrieve]
  17. Fehlhammer, H., Bode, W., and Huber, R. (1977) J. Mol. Biol. 111,415-438 [Medline] [Order article via Infotrieve]
  18. Fersht, A. R. (1972) J. Mol. Biol. 64,497-509 [Medline] [Order article via Infotrieve]
  19. Sigler, P. B., Blow, D. M., Matthews, B. W., and Henderson, R. (1968) J. Mol. Biol. 35,143-164 [Medline] [Order article via Infotrieve]
  20. Sambrook, J. F., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  21. Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,488-492 [Abstract]
  22. Madison, E. L., and Sambrook, J. F. (1993) Methods Enzymol. 223,249-271 [Medline] [Order article via Infotrieve]
  23. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M.-J., and Sambrook, J. F. (1989) Nature 339,721-724 [CrossRef][Medline] [Order article via Infotrieve]
  24. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J., Sambrook, J. F., and Bassel-Duby, R. S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,3530-3533 [Abstract]
  25. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  26. Laemmli, U. K. (1970) Nature 227,680-685 [Medline] [Order article via Infotrieve]
  27. Madison, E. L., Goldsmith, E. J., Gething, M. J., Sambrook, J. F., and Gerard, R. D. (1990) J. Biol. Chem. 265,21423-21426 [Abstract/Free Full Text]
  28. Vassalli, J.-D., and Belin, D. (1987) FEBS Lett. 214,187-191 [CrossRef][Medline] [Order article via Infotrieve]
  29. Ranby, M. (1982) Biochim. Biophys. Acta 704,461-469 [Medline] [Order article via Infotrieve]
  30. Wallen, P., Bergsdorf, N., and Ranby, M. (1982) Biochim. Biophys. Acta 719,318-328 [Medline] [Order article via Infotrieve]
  31. van Mourik, J. A., Lawrence, D. A., and Loskutoff, D. J. (1984) J. Biol. Chem. 259,14914-14921 [Abstract/Free Full Text]
  32. Loskutoff, D. J. (1988) Semin. Thromb. Hemostasis 14,100-109 [Medline] [Order article via Infotrieve]
  33. Robertus, J. D., Kraut, J., Alden, R. A., and Birktoft, J. J. (1972) Biochemistry 11,4293-4303 [Medline] [Order article via Infotrieve]
  34. Bode, W., Schwager, P., and Huber, R. (1978) J. Mol. Biol. 118,99-112 [Medline] [Order article via Infotrieve]
  35. Wang, D., Bode, W., and Huber, R. (1985) J. Mol. Biol. 185,595-624 [Medline] [Order article via Infotrieve]
  36. Kossiakoff, A. A., Chambers, J. L., Kay, L. M., and Stroud, R. M. (1977) Biochemistry 16,654-664 [Medline] [Order article via Infotrieve]
  37. Bennett, W. F., Paoni, N. F., Keyt, B. A., Botstein, D., Jones, A. J. S., Presta, L., Wurm, F. M., and Zoller, M. J. (1991) J. Biol. Chem. 266,5191-5201 [Abstract/Free Full Text]
  38. Paoni, N. F., Chow, A. M., Pena, L. C., Keyt, B. A., Zoller, J. J., and Bennett, W. F. (1993) Protein Eng. 6,529-534 [Abstract]
  39. Madison, E. L. (1994) Fibrinolysis 8,221-236
  40. Hoylaerts, M., Rijken, D. C., Lijnen, H. R., and Collen, D. (1982) J. Biol. Chem. 257,2912-2919 [Abstract/Free Full Text]
  41. Lijnen, H. R., and Collen, D. (1993) Methods Enzymol. 223,197-206 [Medline] [Order article via Infotrieve]
  42. Summaria, L., Hsieh, B., Gros Kopf, W. R., and Robbins, K. C. (1969) Proc. Soc. Exp. Biol. Med. 130,737-741
  43. Reddy, K. N. N., and Markus, G. (1972) J. Biol. Chem. 247,1683-1691 [Abstract/Free Full Text]
  44. Schick, L. A., and Castellino, F. J. (1973) Biochemistry 12,4315-4321 [Medline] [Order article via Infotrieve]
  45. Davidson, D. J., Higgins, D. L., and Castellino, F. J. (1990) Biochemistry 29,3585-3590 [Medline] [Order article via Infotrieve]
  46. Lijnen, H. R., DeCock, F., Matsuo, O., and Collen, D. (1992) Fibrinolysis 6,33-37
  47. Collen, D., Schlott, B., Engelborghs, Y., Van Hoef, B., Hartmann, M., Lijnen, H. R., and Behnke, D. (1993) J. Biol. Chem. 268,8284-8289 [Abstract/Free Full Text]
  48. Hemker, H. C., Bas, B. M., and Muller, A. D. (1975) Biochim. Biophys. Acta 379,180-188 [Medline] [Order article via Infotrieve]
  49. Hendrix, H., Lindhout, T., Mertens, K., Engels, W., and Hemker, H. C. (1983) J. Biol. Chem. 258,3637-3644 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.